Nasdaq · Healthcare
CARLSMED, INC. (CARL)
As-reported financials and recent SEC filings for CARLSMED, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$50.5M
Net income
$-29.6M
Net margin
-58.7%
Diluted EPS
$-2.12
ROE
-30.0%
P/E (TTM)
—
Market cap
—
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2025 |
|---|---|---|
| Revenue | $50.5M | $27.2M |
| Gross profit | $38.0M | $20.0M |
| Operating income | $-30.6M | $-24.1M |
| Net income | $-29.6M | $-24.3M |
| Diluted EPS | $-2.12 | $-2.04 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →8-K2026-06-03
View on EDGAR →10-Q2026-05-05
View on EDGAR →8-K2026-05-05
View on EDGAR →ARS2026-04-22
View on EDGAR →Largest Healthcare peers
Go deeper on CARL
Search CARLSMED, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.